[seopress_breadcrumbs]
About ImPact Biotech
ImPact Biotech is focused on the development and launch of Padeliporfin VTP Therapy, a targeted treatment for selective tumor ablation. The company is headquartered in Israel, with divisions in USA and France as well as its own GMP-certified (Good Manufacturing Practice) facility and research center in Israel.
Leadership
Barak Palatchi
Chief Executive Officer
Eyal Morag
Chief Medical Officer
Roei Sella
Chief Financial Officer
Guy Schmidt
Global Head of Business Development
Louis-Christian Clauss
Global Head of Regulatory Affairs and Pharmaco-Vigilance.
Sharon Yarkoni
Global Head of Quality Assurance
